Ensign Peak Advisors, Inc Macrogenics Inc Transaction History

Ensign Peak Advisors, Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$3.01 - $5.22 $35,578 - $61,700	11,820 New	11,820 $41,000
Q2 2022 Aug 12, 2022	SELL	$2.25 - $9.99 $30,240 - $134,265	-13,440 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$8.12 - $16.9 $3,735 - $7,773	460 Added 3.54%	13,440 $118,000
Q4 2021 Feb 11, 2022	BUY	$15.91 - $21.88 $206,511 - $284,002	12,980 New	12,980 $208,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.